U.S., Sept. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07155382) titled 'Allogeneic HCT Using Conditioning Regimen of BuFluATG for AML CR1' on Aug. 25.
Brief Summary: 1. Study Objectives
* To evaluate the effect of various clinical variables including HLA-disparity and NK cell-related variables, upon outcomes of allogeneic hematopoietic cell transplantation (HCT) using uniform conditioning regimen including busulfan, fludarabine, and antithymocyte globulin (ATG) in patients with acute myeloid leukemia (AML) in the first complete remission (CR). The donors for allogeneic HCT include HLA-matched siblings, matched unrelated donors, and haploidentical family donors.
* The endpoints of the study are engraft...